Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Launched by ANHUI PROVINCIAL HOSPITAL · Mar 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with stage III locally advanced non-small cell lung cancer (NSCLC). The researchers want to see if a type of radiation therapy called hypofraction radiotherapy, followed by a medication that helps boost the immune system (known as an immune checkpoint inhibitor), can improve the effectiveness of the treatment and help control the cancer better than current methods. While current treatments have shown some success, there are still many patients who experience cancer returning in the chest area and beyond, so this trial aims to find a safer and more effective option.

To join the study, participants need to be between 18 and 70 years old, have a specific type of lung cancer that is too advanced to be surgically removed, and have a good overall health status. They will receive the new radiation therapy and follow-up care while being closely monitored for any side effects and how well the treatment works. It's important for potential participants to understand the trial's requirements and to provide informed consent before taking part. The study is currently recruiting, and anyone interested should discuss it with their healthcare provider to learn more about their options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-70 years old;
• • Eastern Cooperative Oncology Group (ECOG) 0-1;
• • Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
• • Wild-type of driven genes;
• • Stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
• • Surgically unresectable or deny of surgery;
• • Signature of inform consent.
• Exclusion Criteria:
• • Younger than 18 years old or older than 70 years old;
• • ECOG\>1;
• • Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
• • Mutant type of driven genes;
• • Non-stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
• • Surgically resectable;
• • No signature of inform consent.